Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients

<p dir="ltr">Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival. However, 15-40% of the patients still fail to respond to ICIs therapy. Identification of b...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Shayista Akbar (14442117) (author)
مؤلفون آخرون:	Afsheen Raza (492657) (author), Reyad Mohsin (14442120) (author), Aladdin Kanbour (14442123) (author), Shahnaz Qadri (2610634) (author), Aijaz Parray (290256) (author), Abdul Rehman Zar Gul (14777347) (author), Anite Philip (14442129) (author), Suma Vijayakumar (14442132) (author), Maysaloun Merhi (4246147) (author), Shereena Hydrose (14442135) (author), Varghese Philipose Inchakalody (14153292) (author), Rajaa Al-Abdulla (14442138) (author), Wafa Abualainin (14442141) (author), Shaza Abu Sirriya (18021691) (author), Issam Al-Bozom (4711098) (author), Shahab Uddin (154400) (author), Omar Muhammad Khan (14442147) (author), Mohamed Izham Mohamed Ibrahim (14158896) (author), Ussama Al Homsi (14442150) (author), Said Dermime (79420) (author)
منشور في:	2023
الموضوعات:	Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis exosomes NSCLC biomarkers immune-checkpoint inhibitors immune-oncological-checkpoints cytokines follow-up
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients

مواد مشابهة